Combination of Multiple Molecular Markers Can Improve Prognostication in Patients With Locally Advanced and Lymph Node Positive Bladder Cancer

Journal of Urology

Volumn 183, Issue 1, 2010, Pages 68-75

  Shariat, Shahrokh F ^a   Chade, Daher C ^c   Karakiewicz, Pierre I ^d   Ashfaq, Raheela ^a   Isbarn, Hendrik ^d   Fradet, Yves ^e   Bastian, Patrick J ^f,g   Nielsen, Matthew E ^h   Capitanio, Umberto ^d,i   Jeldres, Claudio ^d   Montorsi, Francesco ⁱ   Lerner, Seth P ^b   Sagalowsky, Arthur I ^a   Cote, Richard J ^j   Lotan, Yair ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d UNIVERSITÉ DE MONTRÉAL   (Canada)

^e LAVAL UNIVERSITY   (Canada)

^f UNIVERSITY OF BONN   (Germany)

^g LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^h JOHNS HOPKINS HOSPITAL   (United States)

ⁱ VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^j UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

more..

Author keywords

biological markers; immunohistochemistry; recurrence; survival; urinary bladder neoplasms

Indexed keywords

MOLECULAR MARKER; PRB PROTEIN; PROTEIN; PROTEIN P21; PROTEIN P27; PROTEIN P53; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; ADVANCED CANCER; AGED; ARTICLE; BLADDER CANCER; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CARCINOMA IN SITU; CELL CYCLE REGULATION; CYSTECTOMY; DIAGNOSTIC ACCURACY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT DISEASE; SCORING SYSTEM;

EID: 71249096845     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2009.08.115     Document Type: Article

References (30)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2008. CA Cancer J Clin 58 (2008) 71
2. Herr H.W. Surgical factors in bladder cancer: more (nodes) + more (pathology) = less (mortality). BJU Int 92 (2003) 187
3. Herr H.W., Dotan Z., Donat S.M., et al. Defining optimal therapy for muscle invasive bladder cancer. J Urol 177 (2007) 437
4. Herr H.W., Faulkner J.R., Grossman H.B., et al. Surgical factors influence bladder cancer outcomes: a cooperative group report. J Clin Oncol 22 (2004) 2781
5. Madersbacher S., Hochreiter W., Burkhard F., et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J Clin Oncol 21 (2003) 690
6. Stein J.P., Lieskovsky G., Cote R., et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19 (2001) 666
7. Shariat S.F., Karakiewicz P.I., Palapattu G.S., et al. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol 176 (2006) 2414
8. Shariat S.F., Karakiewicz P.I., Ashfaq R., et al. Multiple biomarkers improve prediction of bladder cancer recurrence and mortality in patients undergoing cystectomy. Cancer 112 (2008) 315
9. Sarkis A.S., Dalbagni G., Cordon-Cardo C., et al. Nuclear overexpression of p53 protein in transitional cell bladder carcinoma: a marker for disease progression. J Natl Cancer Inst 85 (1993) 53
10. Esrig D., Elmajian D., Groshen S., et al. Accumulation of nuclear p53 and tumor progression in bladder cancer. N Engl J Med 331 (1994) 1259
11. Stein J.P., Ginsberg D.A., Grossfeld G.D., et al. Effect of p21WAF1/CIP1 expression on tumor progression in bladder cancer. J Natl Cancer Inst 90 (1998) 1072
12. Tokunaga H., Shariat S.F., Green A.E., et al. Correlation of immunohistochemical molecular staging of bladder biopsies and radical cystectomy specimens. Int J Radiat Oncol Biol Phys 51 (2001) 16
13. Cote R.J., Dunn M.D., Chatterjee S.J., et al. Elevated and absent pRb expression is associated with bladder cancer progression and has cooperative effects with p53. Cancer Res 58 (1998) 1090
14. Benedict W.F., Lerner S.P., Zhou J., et al. Level of retinoblastoma protein expression correlates with p16 (MTS-1/INK4A/CDKN2) status in bladder cancer. Oncogene 18 (1999) 1197
15. Cordon-Cardo C., Wartinger D., Petrylak D., et al. Altered expression of the retinoblastoma gene product: prognostic indicator in bladder cancer. J Natl Cancer Inst 84 (1992) 1251
16. Chatterjee S.J., Datar R., Youssefzadeh D., et al. Combined effects of p53, p21, and pRb expression in the progression of bladder transitional cell carcinoma. J Clin Oncol 22 (2004) 1007
17. Shariat S.F., Tokunaga H., Zhou J., et al. p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer. J Clin Oncol 22 (2004) 1014
18. Shariat S.F., Zlotta A.R., Ashfaq R., et al. Cooperative effect of cell-cycle regulators expression on bladder cancer development and biologic aggressiveness. Mod Pathol 20 (2007) 445
19. Shariat S.F., Ashfaq R., Sagalowsky A.I., et al. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma. J Urol 177 (2007) 481
20. Shariat S.F., Margulis V., Lotan Y., et al. Nomograms for bladder cancer. Eur Urol 54 (2008) 41
21. Shariat S.F., Palapattu G.S., Karakiewicz P.I., et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur Urol 51 (2007) 137
22. Shariat S.F., Ashfaq R., Sagalowsky A.I., et al. Correlation of cyclin D1 and E1 expression with bladder cancer presence, invasion, progression, and metastasis. Hum Pathol 37 (2006) 1568
23. Sarkis A.S., Bajorin D.F., Reuter V.E., et al. Prognostic value of p53 nuclear overexpression in patients with invasive bladder cancer treated with neoadjuvant MVAC. J Clin Oncol 13 (1995) 1384
24. Cote R.J., Esrig D., Groshen S., et al. p53 and treatment of bladder cancer. Nature 385 (1997) 123
25. Grambsch P.M., and Therneau T.M. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika 81 (1994) 515
26. Fine J.P. Regression modeling of competing crude failure probabilities. Biostatistics 2 (2001) 85
27. Harrell Jr. F.E., Lee K.L., and Mark D.B. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15 (1996) 361
28. David K.A., Milowsky M.I., Ritchey J., et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998 to 2003: a report from the National Cancer Data Base. J Urol 178 (2007) 451
29. Shariat S.F., Kim J., Raptidis G., et al. Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology 61 (2003) 1140
30. Grossman H.B., Liebert M., Antelo M., et al. p53 and RB expression predict progression in T1 bladder cancer. Clin Cancer Res 4 (1998) 829